Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal (GI) tract. Although they have been recognized as a distinct entity for several decades, it has only been over the past 10-15 years that these tumors have been truly studied and further defined by rigorous diagnostic and molecular criteria. Indeed, one might argue that it was a landmark study involving the successful treatment of unresectable GIST that launched a new era of targeted therapy in clinical oncology. In the ensuing years we have further refined our knowledge of GIST, developed rigorous diagnostic techniques, surgical interventions and prognostic criteria. Considerable strides have also been made in adjuvant therapy of successfully resected localized tumors and in the setting of widespread disease. In this article, we review the recent progress that has been made in all of these domains.
A study from Japan suggested that the incidence of asymptomatic GIST may be much higher than hitherto suspected and it has been proposed that only a few of the very small incidental tumors may actually develop into larger ones with malignant potential. 5 GIST may be associated with nonspecific symptoms such as abdominal discomfort, bloating, and early satiety. When the tumor is ulcerated or large enough to elicit symptoms, patients may present with overt GI bleeding (40 %), abdominal pain (40 %), or an abdominal mass (20 %). 6 Over 25 % of patients may present with bowel obstruction. Bowel perforation, in the setting of GIST, occurs infrequently. In the case of esophageal GIST, dysphagia may represent the first site-specific symptom. Interestingly, paraneoplastic syndromes involving hypoglycemia 7 or hypothyroidism have been described. 8 
Unusual Clinical Presentations

GIST Syndromes
In adults, GIST has been associated with neurofibromatosis type 1 (NF1) 9 and the Carney triad 10 /syndrome 11 (gastric epithelioid GIST, extra-adrenal paraganglioma, and pulmonary chondroma).
• NF1-associated GIST has a propensity for multicentricity within the GI tract, spindle cell morphology and do not harbor KIT or plateletderived growth factor receptor alpha (PDGFRA) gene mutations. NF1-associated GIST is typically positive for the CD117 antigen.
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• Carney triad syndrome-associated GIST is predominantly of epithelioid morphology, tends to occur in the antrum of the stomach, lacks conventional KIT and PDGFRA gene mutations, and tend to run an indolent course. 9, 12, 13 • GIST-paraganglioma syndrome is extremely rare and is similar to the Carney triad, but lacking pulmonary chondroma with an equal gender distribution and is also referred to as the Carney Stratakis syndrome. 
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Pediatric GIST-These are rare (1-2 % of all GIST) and fall into one of two subgroups: with mutations (either KIT or PDGFRA) or without mutations, the latter being more frequent. The patients are almost exclusively young females, developing gastric epithelioid GIST, which are KIT positive by immunohistochemistry (IHC). Unlike adult GIST, these tumors can spread to lymph nodes.
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Multiple GIST-Notwithstanding the above described GIST syndromes, sporadic, synchronous, and metachronous tumors have been observed in patients without identifiable germ line risk factors, suggesting that other genes that predispose to the development of GIST have yet to be discovered.
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Diagnosis
Preoperative pathologic diagnosis usually is not required if imaging is consistent with a GIST, the tumor is resectable without significant morbidity, and the patient is an operative candidate. Typically on computed tomography (CT) scan, a GIST appears as a smoothly contoured mass that enhances brightly with intravenous contrast (see Figure 2A /B). Very large tumors may appear more complex due to necrosis, hemorrhage, and degenerating components. In cases where operative morbidity is high or the diagnosis is unclear, biopsy may be warranted. If biopsy is required, endoscopic ultrasound guided fine needle aspiration (EUS-FNA) biopsy is an acceptable option and can be a safe and reliable way to obtain the diagnosis and is associated with a lower risk for seeding or potential spread of disease. In a study of 65 patients, EUS-FNA had a sensitivity of 82 % and a specificity of 100 %. 18 Another method of biopsy that can be used is endoscopic ultrasound-guided trucut biopsy.
This type of biopsy also allows for high agreement between biopsy and surgical pathology specimen with respect to yield of diagnosis and CD117
status. 19 Percutaneous biopsy carries the risk for tumor capsule rupture with peritoneal spread of disease 20 and thus is avoided if at all possible.
However, in selected cases, careful, guided percutaneous biopsy by expert radiologists may be attempted when a neoadjuvant approach is being considered or if there is diagnostic uncertainty and there is no ability to perform an EUS-guided biopsy. Pathology and Differential Diagnosis of GIST GIST appears to originate from the ICC or their stem cell-like precursors. 21, 22 ICCs are pacemaker-like cells located between the layers of the muscularis propria throughout the GI tract, which regulate GI motility and autonomic nerve function. ICC or their stem cell-like precursors can differentiate into smooth muscle cells if KIT gene signaling is disrupted. 23 The morphologic spectrum of GIST includes spindle cell tumors, with thin, elongated nuclei forming long, interlacing fascicles (see Figure 3A /B), and epithelioid tumors, with polygonal cells in a syncytial pattern, without visible cell borders and large, round nuclei (see Figure 3 C/D) . Based on morphology, [24] [25] [26] GIST can be subtyped into the following categories:
• Spindle cell variants: sclerosing, palisading-vacuolated, hypercellular, and sarcomatous spindle cell; and
• Epithelioid cell variants: sclerosing, discohesive, and hypercellular epithelioid.
Based on nuclear atypia, presence of necrosis, hemorrhage and mitotic activity, the tumors can appear very bland and cytologically benign (see Figure 4 A/B), or frankly malignant (see Figure 4 C/D).
Immunohistochemistry of GIST
KIT (CD117)-In recent years, IHC staining for KIT expression (CD117) has become integral to the diagnosis of GIST, nearly 90 % of which harbor activating mutations in the KIT receptor tyrosine kinase gene. 27 Approximately 95 % of GIST are positive for the CD117 antigen by IHC staining. 12 The staining pattern may be cytoplasmic, membranous, and/or paranuclear (Golgi pattern) (see Figure 5 A/B/C). Although KIT positivity is a major defining feature of GIST, it is no longer an absolute requirement; KIT expression is a constitutional feature and not a consequence of the mutation. Moreover, a GIST having a weak or negative KIT expression tends to be KIT wild-type or PDGFRA mutants. In rare cases, tumors cease to express the KIT protein because of clonal evolution after tyrosine kinase therapy.
CD117 is not specific for GIST. In fact, weak reactivity can occur with other mesenchymal neoplasms. Accordingly, CD117 immunostaining of tumors should be interpreted cautiously in the context of other immunomarkers and the anatomic location and morphology of the tumor in order to differentiate GIST from other mesenchymal, neural, and neuroendocrine neoplasms.
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DOG1 ("discovered on GIST 1")-This is a protein of unknown function that is expressed strongly on GIST and is rarely expressed on other soft tissue tumors. 28 The staining pattern of DOG1 varies from cytoplasmic to membranous, with usually strong, diffuse intensity (see Figure 6 ).
The results from several series have shown a high overall sensitivity and specificity for DOG1 in the detection of GIST. Overall, about 6 % of GIST exhibit a DOG1+/KIT-immunoprofile. [28] [29] [30] DOG1 antibodies are more sensitive than KIT antibodies in detecting tumors of gastric origin, tumors with epithelioid morphology, and tumors harboring PDGFRA mutation.
28-31
Protein Kinase C Theta (PKC-θ)-This is a novel PKC isotype involved in T-cell activation, and is highly and specifically expressed in GIST showing a diffuse cytoplasmic staining pattern. Although PKC-θ has a lower specificity than DOG-1, it can be a useful biomarker, especially in CD117/ DOG1-negative GIST. [32] [33] [34] Of note, PKC-θ is also reported to be expressed Neural markers such as S100 are observed in <1 % of GIST.
In summary, an IHC panel including KIT (CD117), DOG1, S100, desmin, SMA, and CD34 are useful to confirm the diagnosis of GIST and help distinguish GIST from other mesenchymal tumors. c-KIT, PKC-θ, and DOG1 antigens are the most sensitive and specific immunomarkers for confirming extraintestinal GIST.
Differential Diagnosis of GIST
The tumors that enter the differential diagnosis of GIST vary widely according to the histologic pattern, and can be grouped into tumors with spindled or epithelioid morphology, either cytologically bland or frankly malignant.
Spindle Cell Tumors, Cytologically Bland
Included in these are the following:
• Abdominal/mesenteric fibromatosis is the most common primary tumor of the mesentery. This entity is usually CD117 negative and shows strong nuclear positivity with β catenin. 37, 38 • Leiomyomas commonly occur in the esophagus and rectum and are true neoplasms of smooth muscle origin. By IHC, they are positive for smooth muscle markers (desmin, SMA, muscle specific actin [MSA]) and negative for CD117 and DOG1.
• Schwannomas are rare benign mesenchymal tumors, common in the stomach, colon, and rectum. By IHC they commonly express glyofibrillar acid protein (GFAP) and S100 but are negative for CD117
and DOG1. They also usually do not express the NF2 gene alterations commonly seen in typical soft tissue schwannomas.
• Inflammatory fibroid polyps are most common in the submucosa of the gastric antrum and are rare in the small intestine, colon, and esophagus. These are hypocellular tumors, with loose edematous stroma, "onion skin" arrangement of spindle cells around vessels, and numerous inflammatory cells, especially eosinophils. By IHC they express CD34, focal positivity for SMA, but usually lack expression of CD117 and DOG1. • Malignant melanoma-This is the most common solid tumor that metastasizes to the GI tract, especially the small intestine. Amelanotic melanoma can be misdiagnosed as a GIST, carcinoma, or sarcoma. A potential pitfall in its diagnosis is the fact that >75 % of melanomas can express CD117. However, most melanomas express S100, HMB45, Melan A, and tyrosinase, but lack DOG1.
• Sarcomatoid carcinoma-Either primary or metastatic to the GI tract, can be diagnosed if the epithelial origin is confirmed by keratin stains (low-or high-molecular keratins) and/or the presence of epithelial dysplasia at the edge of the tumor.
• Leiomyosarcoma-Is an uncommon, high-grade tumor, showing infiltrative margins, high mitotic rate, and marked nuclear pleomorphism.
By IHC, like their benign counterpart, they express smooth muscle markers (desmin, SMA, MSA, h-caldesomon) but lack CD117 and DOG1.
• Malignant peripheral nerve sheath tumor (MPNST) -These are extremely rare tumors that arise from a peripheral nerve or exhibit nerve sheath differentiation. They are highly cellular tumors, with a high mitotic rate, necrosis and marked nuclear pleomorphism. Unlike schwannomas, they show very focal S100 positivity, and are negative for CD117, DOG1, and HMB45. 
Epithelioid Cell Tumors, Cytologically Bland
This group includes the following:
• Glomus tumors-These tumors have been well described in the • Epithelioid schwannomas-These are rare benign lesions of the colon or rectum, strongly positive for S100; negative for CD117 and DOG1.
• Paragangliomas-Usually of the duodenum, can be epithelioid, ganaglion-like, or spindle cell, with a nested pattern, show neuroendocrine expression with synaptophysin, chromogranin A, and lack CD117 and DOG1. They comprise part of the Carney syndrome 11, 44 (gastric epithelioid GIST, extra-adrenal paraganglioma, and pulmonary chondroma).
Epithelioid Cell Tumors, Cytologically Malignant
The main considerations in this group include malignant melanoma, poorly differentiated carcinoma, epithelioid leiomyosarcoma, and neuroendocrine tumors, which can be differentiated by clinical history, imaging, and IHC.
Molecular Classification of GIST
Approximately 85 % of GISTs contain oncogenic mutually exclusive mutations in one of two receptor tyrosine kinases: KIT or PDGFRA. 12 Constitutive activation of either of these receptor tyrosine kinases plays a central role in the pathogenesis of GIST. 21 The proper identification of GIST with genotyping is very important because of the availability of specific, molecular-targeted therapy with KIT/PDGFRA tyrosine kinase inhibitors (TKIs), such as imatinib mesylate, or, in the case of imatinib-resistant GIST, sunitinib maleate. [45] [46] [47] GIST may fall into one or more of the following subgroups ( Table 1) :
Approximately 80 % of all GISTs contain a mutation in the KIT receptor tyrosine kinase that results in constitutive activation of the protein. 12 The KIT gene is located on chromosome 4q12-13, in the vicinity of genes encoding the receptor tyrosine kinases PDGFRA, However, recent studies have revealed that wild-type GISTs are a heterogeneous group and display various oncogenic mutations (see Table 1 ). For example, the BRAF V600E substitution that is seen in papillary thyroid carcinoma and melanoma is present in up to 7-15 % of wild-type GIST. 55 Defects in the succinate dehydrogenase (SDH) complex of respiratory chain complex II, which comprises four subunits (SDHA, SDHB, SDHC, and SDHD), have recently been identified in wildtype GIST. 56 Germline mutations in SDHB, SDHC, or SDHD increase the risk not only of the development of GIST, but also of the development of paragangliomas (Carney Stratakis syndrome). 65 This study supported laparoscopic resection stating that it was safe and effective and was associated with a significantly shorter length of hospital stay. This technique is thus feasible in well-selected patients.
As has been aforementioned, the major breakthrough in the management of GIST came about with the development of TKIs-small molecules such as imatinib and others that followed suit, which have revolutionized the OncOlOGy & HemaTOlOGy Review management of this disease and have prompted investigation of similar approaches in the wider field of oncology. The major studies investigating imatinib are well known and are summarized in Table 2 .
Neoadjuvant Therapy
In cases of borderline resectable or potentially resectable disease, which requires extensive organ disruption, initial therapy with the TKI, imatinib, is a rational approach. This allows for downstaging of the tumor for possible resection. Figure 7A /B shows an example of a large borderline resectable GIST that becomes resectable after several months of neo-adjuvant imatinib treatment. There is limited published data on neo-adjuvant therapy in GIST: most of the information has been based on the high response rate to imatinib in the setting of locally advanced or metastatic disease and on small retrospective study reports. [66] [67] [68] In a study by Andtbacka, 46 patients who underwent potentially curative surgery after initial treatment with imatinib were assessed retrospectively for surgical resection rate and outcome. 66 Of them, 11 with locally advanced disease were treated for a median 11.9 months, followed by complete resection, and were alive at a median of 19.5 months (10 were disease free The
largest series thus far of patients treated with neoadjuvant imatinib is from the European Organisation for Research and Treatment of Cancer-Soft
Tissue and Bone Sarcoma Group (EORTC-STBCG). 72 In this series, overall survival (OS), disease-free survival (DFS), and DSS in 161 patients with locally advanced, nonmetastatic GIST who received neoadjuvant imatinib, were analysed. The primary tumor was in the stomach (55 %), rectum (20 %), duodenum (10 %), ileum/jejunum/other (11 %), and esophagus (3 %).
Sixty-five percent of patients had an exon 11 mutation. The tumor resection after neoadjuvant imatinib (median time on therapy, 40 weeks) was R0 in 83 % of cases. Only two patients had disease progression on therapy. Fiveyear DSS and DFS were 95/65 %, respectively. Median OS was 104 months and median DFS was not reached. Thirty-seven GIST recurrences were diagnosed (only five of which were local recurrences). Fifty-six percent of patients continued imatinib therapy post resection and these patients did better than those who did not have post-operative therapy.
There is no consensus on the duration of neo-adjuvant treatment with imatinib in the setting of locally advanced or recurrent potentially resectable GIST. It has been suggested to treat patients from 3 to 12 months with frequent imaging as long as radiologic tumor response is evident 73 with planned surgery thereafter in responding patients. The recommended dose is 400 mg daily; however, in KIT exon 9 mutations, dose escalation to 800 mg may be considered.
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Adjuvant Therapy
All GISTs have some malignant potential and may recur or metastasize following apparent curative, margin-negative resection. Tumors of the small intestine behave more aggressively than those in the stomach.
Thus, 40-50 % of small bowel GIST, demonstrate malignant behavior in contrast to 20-25 % in gastric GIST. 25 There is paucity of data on GIST behavior in such unusual sites as the esophagus, colon, and rectum. Clinical management thus depends on GIST malignancy risk stratification that is determined by tumor size, location, and number of mitoses on final surgical pathology. 74, 75 The risk scheme and stratification developed by Miettinen et al. is widely considered the most reliable and has been adopted worldwide (see Table 3 ). As well, EUS has been used to identify possible high-risk features, such as ulceration, echogenic foci, irregular borders, cystic spaces, and heterogeneity to aid in management decision-making. Although the results of this trial formed the basis for the recommendation for adjuvant imatinib in many jurisdictions, it also raised many questions.
It was observed that 1 year after imatinib discontinuation, the rate of recurrence in the imatinib-treated population was similar to the control arm. This may imply that longer duration of treatment is required. Also, in this study, the inclusion criteria listed only tumor size as a prerequisite leaving the role played by other risk criteria such as mitotic rate, tumor site, and molecular factors unanswered.
In the EORTC 62024 phase III trial, 908 patients were treated with imatinib . 81 It was noted however that more patients in the prolonged treatment arm discontinued therapy for reasons other than disease progression (26 % versus 13 %). As in the ACOSOG Z9001 trial, the rates of disease recurrence in the control and treatment arms within 6-12 months after imanitib discontinuation were similarly increased that rose once again, the important issue of the optimum duration of therapy.
Most clinical practice guidelines now recommend the use of adjuvant imatinib 400 mg daily for 3 years for patients with high-risk GIST. The selection of patients should be based on accepted risk classifications, such the Miettinen criteria described earlier. Mutational analysis may also provide additional predictive information for benefit from adjuvant imatinib.
In the Z9001 study, subgroup analysis indicated that those patients with exon 11 (deletion or no deletion) and PDGFRA mutations experienced benefit from 1 year of adjuvant treatment. Similarly, in the SSG XVIII trial, significant benefit favoring 3 years of adjuvant therapy was only observed 
Follow-up Recommendations of Localized or Resected GIST
There is no high level evidence that addresses the optimum surveillance strategy for patients with an early-stage, localized (treated or untreated) GIST.
For patients with a resected GIST, National Comprehensive Cancer Network (NCCN) recommendations include a physical examination with a thorough history and a CT scan of the abdomen and pelvis every 3 to 6 months for the first 5 years, and then annually.
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In cases of small gastric GIST (less than 2 cm), with low-risk EUS features that is being followed in the absence of surgery, endoscopic surveillance every 6 to 12 months is recommended.
The European Society of Medical Oncology (ESMO), in their recommendations, tailors follow-up frequency to tumor high-risk features. 82 Thus for very-lowrisk GIST, routine surveillance is not recommended.
Management of Metastatic or Unresectable Disease
The small molecule tyrosine kinase protein inhibitor, imatinib, is now accepted as the standard first-line treatment for unresectable or metastatic GIST. With the introduction of imatinib, the median OS of patients with unresectable or metastatic disease has increased from 18 to 57 months. 83 Multiple phase II and III studies have confirmed the benefit of imatinib in this setting demonstrating high response rates and improved PFS. 39, [84] [85] [86] [87] Two phase III trials compared two dose levels of imatinib (400 mg versus 800 mg daily) in the setting of advanced GIST. No statistical differences were observed between the two doses and the higher dose was associated with more side effects in both studies. An initial dose of 400 mg per day is now widely agreed upon as the appropriate first-line therapy. Long-term follow up in two studies has confirmed the potential durable effect of imatinib. In the SWOG phase III trial S0033, 26 % of patients treated with two different doses of imatinib survived 8 years or longer, with a projected 10-year survival of 22 %. 86, 87 Although these major studies completely altered the course of management of patients with GIST, it is a sobering reality that complete responses are infrequently observed (in less than 10 % of patients). Most patients eventually develop resistance to imatinib and progress within 2 to 3 years. 47 The question regarding the optimal duration of therapy was addressed in the BFR14 phase III trial. 88 Patients with unresectable/metastatic GIST, stable on treatment for 1 year were randomly assigned to continue therapy or interrupt treatment until disease progression. This study was halted prematurely as it observed evidence that treatment interruption resulted in rapid disease progression even in apparent complete responders. Median PFS was 18 months versus 6 months in favor of continuous therapy. The trial authors concluded that treatment should be lifelong or until disease progression.
In these above referenced studies, it also became apparent that response assessment when using novel biologic agents needed to be addressed.
To assess a response to treatment, patients conventionally undergo CT imaging and 2D measurements are used to designate response, stability, or progression. However, during treatment with imatinib, a responding GIST may actually increase in size secondary to necrotic changes or hemorrhage. For this reason and for assessment purposes, both RECIST and Choi criteria (which takes into account tumor density changes in contrast-enhanced CT scans), should be employed. as outlined below should be considered (see Table 4 ).
Role of Surgery in Metastatic Disease
As mentioned above, despite lasting disease control, complete responses with imatinib are rare. 93 Most patients on imatinib eventually develop resistance and progress within 2 to 3 years. 94 For these reasons surgical resection has been considered in responders with limited metastatic disease burden and potentially resectable disease. There are no results of prospectively conducted trials that conclusively support this approach.
However, single-institution retrospective reviews have reported longterm disease control with resection of metastatic disease in responders following treatment with imatinib. 66, 67, 95, 96 In the largest analysis by the EORTC-STBSG evaluating surgery in metastatic disease, 239 patients with metastatic GIST underwent metastasectomy and received imatinib therapy. Complete resection (R0/R1) was achieved in 177 patients. Median OS was 8.7 years for R0/R1 and 5.3 years in patients with R2 resection.
In the group who were in remission at the time of resection, median OS was not reached in the R0/R1 surgery and was 5.1 years in the R2 surgery. Median time to relapse/progression after resection of residual disease was not reached in the R0/R1 group and was 1.9 years in the R2 group, who were resected in response. This analysis shows possible long-term survival in patients in whom surgical complete remission can be achieved. Debulking surgery does not seem to prolong survival. 96 After complete resection, most experts recommend continuation of imatinib as the risk for recurrence upon discontinuation of therapy remains high.
84 Figure 8 demonstrates the specimen of a GIST metastasectomy. 
Role of Locoregional Treatment in Metastatic GIST
Beyond Imatinib
For patients with primary or secondary resistance to imatinib, dose escalation is a viable option. 86 In a European trial, which assessed standard versus high-dose imatinib, 247 out of the 473 patients on the low dose regimen progressed and 133 of them were crossed over to the higher dose. 99 Of these, 36 patients had a prolonged period of stable disease with three patients having a confirmed partial response. These results were confirmed by an American study involving 164 patients. 87 One hundred and thirty-three of those who progressed on the conventional dose of imatinib crossed over to 800 mg daily; 33 % of assessable patients had either stable disease or response with a median PFS of 5 months and OS of 19 months after cross over.
In patients with imatinib intolerance or secondary resistance to medication the second-line multitarget TKI sunitinib is recommended. [100] [101] [102] In an international phase III trial of sunitinib versus placebo, 312 patients with imatinib resistance were randomized either to sunitinib or placebo.
Those who progressed on placebo crossed over to the treatment arm.
At a median follow up of 42 months, median time to tumor progression was 27 weeks on sunitinib versus 6 weeks on placebo. 103 Median OS was reported as 73 versus 66 months in favor of the sunitinib arm. Of interest, as previously discussed, in patients with a KIT exon 9 mutation, or a wild-type KIT/PDGFRA mutation, the rate and duration of response with sunitinib was much higher than for those patients with a KIT exon 11 mutation. 101 Sunitinib is now considered appropriate therapy for patients who progress on imatinib as second-line therapy.
Finally, another multikinase inhibitor, regorafenib has been prospectively evaluated in imatinib-and sunitinib-resistant patients as third-line therapy. The activity of regorafenib in such patients was first observed in a phase II trial conducted by George et al. 104 These data were confirmed in a phase III trial where 199 patients with refractory disease or intolerance to sunitinib were randomized to regorafenib or best supportive care (BSC). 105 Reported PFS was 4.8 versus 0.9 months in favor of the treatment arm; no survival benefit was observed, possibly due to cross over of patients who progressed on BSC.
Over the past few years the availability of novel agents has steadily expanded. These include nilotinib, which has also demonstrated activity in this area. 106, 107 However, its role in GIST refractory to both imatinib and sunitinib is less defined. In a phase III trial of 248 patients who failed treatment with both imatinib and sunitinib, patients were assigned to nilotinib or BSC: no significant differencs in outcome were reported. recommended in high-risk tumours. 76, 110 In the setting of locally advanced primary unresectable disease, neoadjuvant treatment for 3 to 6 months may be considered. [66] [67] [68] 72 In patients with metastatic or unresectable disease, treatment with imatinib is associated with significant improvements in OS from 18 to 57 months. 83 In patients with metastatic disease responding to imatinib, complete metastasectomy if feasible can allow for possible long-term survival; however, debulking surgery with R2 resection is not beneficial. 96 Other locoregional treatments such as RFA or hepatic artery embolization with or without chemotherapy may achieve long-lasting disease control and may be considered in highly selected patients. 97, 98 In patients with primary or secondary resistance to imatinib, second-line treatment with sunitinib or third-line therapy with regorafenib is recommended; 102, 106 imatinib dose escalation is a viable option. 86 However, despite all of these advances, few patients with metastatic disease are cured and further trials of novel agents or combinations are still required (see Algorithm 1 and 2). ■ 
